Podcasts about healthtech

Still in his early twenties Matthew Payne parked his career plans and degree course to work for a tech start-up to try, as he puts it, to fix the National Health Service. Matthew was due to finish his final undergraduate year and had ticked all the boxes to make himself a good candidate for a well-paid traineeship in corporate law.So what drives a person to work in a tech start-up facing such a tricky task – risky even if you believe in its products, the founders and can see that it might be going places?The answer, in part, lies in Matthew's strong ethical values, his sense of social responsibility and his push for sustainability.With more than 1000+ GP practices in England signed up for Healthtech-1's support, the firm is already making a difference and is looking to expand and improve its offerings.Listen to the podcast to hear Matthew's thoughts on taking on voluntary roles, the benefits of part-time work and of getting involved in new things at university. He runs through ideas for what might happen later in his career and emphasises the importance of getting young people's voices into the places that matter. Mentioned in this podcastLinksHealthtech-1Sustainable Recruitment AllianceY CombinatorScience and Tech investment to ignite UK Growth Do you need a degree to work in tech? (BBC)Student MindsWorcester UniversityReading University Other episodes you might like to listen toLaura Yeates and Leora Schlasko – Sustainable recruitment alliance S1 E3James Adeleke – Founder and CEO of Generation Success. Equality champion S4 E5Maddie Booth – Sustainability consultant, educator and speaker S4 E6Stuart Goldsmith – Climate comedian and podcaster S5 E2About ProGRESS:Host Sandra Kessell invites guests to discuss their pro- Green, Ethical, Sustainable and Socially responsible jobs, courses or activities and asks for real-world insights into the pathways and careers that led to them. Subscribe and find out how they got there and how you can too.Instagram: @progress_green_careers_podcastOriginal content © Sandra Kessell Original music © Lyze KessellEmail: hello@mypro-gress.co.uk Hosted on Acast. See acast.com/privacy for more information.

Most medical care is backed by varying types of evidence, yet we apply higher standards to digital health tools before they're trusted, adopted, or reimbursed.In this special episode, guest host Lucia Savage is joined by Dr. Vindell Washington of Verily and Dr. Aaron Carroll of AcademyHealth for a candid conversation about the uneven standards we apply to digital versus traditional care. Together, they explore how we define evidence, whose voices shape that definition, and what it takes to build trust in an AI-powered healthcare future.We cover:

Do you want to explore some non traditional ways to use your medical degree- but you are unsure where to start?This episode is your ultimate quick start guide to exploring the world of Health Tech.In this interview with Lauren Curtis of Hey Health Tech, you will learn:➡️ How to create your dream postion using intrapreneuership➡️ Why trying to make a 10 year plan for your career is limiting your possibilities and keeping you stuck➡️ A fun technique to start brainstorming and exploring new, exciting career opportunities.Press play now to get ideas for your next career move!Register for Pivot Potentials Now >> https://coachchelsmd.com/summit/ Life After Medicine explores doctors' journey of finding purpose beyond their medical careers, addressing physician burnout, career changes, opportunities in non-clinical jobs for physicians and remote jobs within the healthcare system without being burned out, using medical training.

How do you patent health tech inventions in today's challenging IP landscape, especially when AI is reshaping the game? We explore the complex world of patenting health technology inventions with Ryan Phelan, U.S. Patent Attorney and Partner at Marshall, Gerstein & Borun LLP. Health tech innovations, from AI-powered diagnostic tools to surgical robotics, often face unique patent hurdles. This is especially true under the U.S. Patent Office's evolving guidelines.  What you'll learn: Why many health tech patents get rejected as "organizing human activity" Proven strategies and workarounds to successfully patent healthcare IT and software-driven medical devices The explosive growth of AI patents in healthcare and what it means for innovators  Tips for healthcare startups and executives to protect their breakthroughs and intellectual property If you're working in healthcare innovation, med tech, medical device development, AI in health, or intellectual property law, this episode offers essential insights to help you safeguard your inventions. Find Ryan's work at: www.marshallip.com Subscribe and stay at the forefront of the digital healthcare revolution. Watch the full video on YouTube @TheDigitalHealthcareExperience The Digital Healthcare Experience is a hub to connect healthcare leaders and tech enthusiasts. Powered by Taylor Healthcare, this podcast is your gateway to the latest trends and breakthroughs in digital health. Learn more at taylor.com/digital-healthcare About Us: Taylor Healthcare empowers healthcare organizations to thrive in the digital world. Our technology streamlines critical workflows such as procedural & surgical informed consent with patented mobile signature capture, ransomware downtime mitigation, patient engagement and more. For more information, please visit imedhealth.com   The Digital Healthcare Experience Podcast: Powered by Taylor Healthcare Produced by Naomi Schwimmer  Hosted by Chris Civitarese Edited by Eli Banks Music by Nicholas Bach  

In this episode, hosts Ajay Mody and Asher Perzigian sit down with Rivka Friedman, Head of Health Innovation at Morgan Health, to explore how JPMorgan is reengineering the employer-sponsored healthcare system. Rivka unpacks how Morgan Health's dual engine of investment and innovation is driving a smarter, more outcomes-focused model—scaling value-based care, piloting advanced primary care, and addressing critical gaps in maternal health and affordability.   The conversation dives into the complexities of aligning incentives in commercial insurance, the power of data in improving outcomes, and why small and mid-sized businesses are emerging as a new frontier for healthcare transformation. Whether you're a founder, policymaker, or just health-curious, this episode delivers bold ideas and practical insights for building a more resilient and equitable healthcare future.

Most AI in healthcare promises superintelligence—but what if that's the wrong goal entirely?In this episode, Michael and Halle speak with Othman Laraki, co-founder and CEO of Color Health, to talk about why real-world care doesn't need a perfect model—it needs a better system. Othman breaks down how Color evolved from a consumer genetics startup into a nationwide virtual cancer clinic, why most diagnostics businesses fail, and how AI can actually support clinicians without trying to replace them.We cover:

Ruth Goble, Operations Executive at the MedicAlert Foundation of Southern Africa, speaks to Lester Kiewit about which option is more effective in an emergency. She unpacks the importance of immediate access to critical medical information and weighs up the question: Is it better to wear your medical info or save it on your phone in a crisis? Good Morning Cape Town with Lester Kiewit is a podcast of the CapeTalk breakfast show. This programme is your authentic Cape Town wake-up call. Good Morning Cape Town with Lester Kiewit is informative, enlightening and accessible. The team’s ability to spot & share relevant and unusual stories make the programme inclusive and thought-provoking. Don’t miss the popular World View feature at 7:45am daily. Listen out for #LesterInYourLounge which is an outside broadcast – from the home of a listener in a different part of Cape Town - on the first Wednesday of every month. This show introduces you to interesting Capetonians as well as their favourite communities, habits, local personalities and neighbourhood news. Thank you for listening to a podcast from Good Morning Cape Town with Lester Kiewit. Listen live on Primedia+ weekdays between 06:00 and 09:00 (SA Time) to Good Morning CapeTalk with Lester Kiewit broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/xGkqLbT or find all the catch-up podcasts here https://buff.ly/f9Eeb7i Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

How do you lead at the cutting edge of health, data, and AI—while staying deeply human?Angeli Möller has led global data science teams across pharma giants, co-founded one of Europe's most ambitious AI alliances, and now builds high-performance biotech strategies with precision. But what truly sets her apart isn't just her technical fluency—it's her clarity, courage, and care in how she builds teams, solves problems, and pushes the boundaries of innovation.In this episode, Angeli opens up about the quiet frustrations that fuel her mission, the invisible cost of ignoring innovation, and the principles that guide her client work today. Whether you're an investor, founder, or policymaker, her journey will reshape how you think about leadership, AI, and what truly moves the needle in healthcare.Here's what you'll take away:Why most AI projects fail—and how to spot the ones that won't.How to lead technical teams with vision, warmth, and accountability.Why proprietary data matters more than fancy algorithms.What real innovation feels like—and how to know when you're missing it.At the center of it all: a calm, fiercely smart leader who sees through the noise and builds what matters.As she says: “Start with the real problem. If you don't understand the problem, AI won't help you.”Timestamps & Topics

SomX's Jessica Somauroo and Amy Thomas dive into the weeks' healthtech stories.00:00 - Intro17:28 - Public health bodies urged to launch period tracking apps to protect data

Takk for at dere lytter til denne podcasten med Karl Oscar og Richard.

Mike Wieger joins me to talk through the latest in home tech and personal gadgets. We cover his switch from Cox to MetroNet fiber and compare Omaha's evolving internet options, including T-Mobile and Great Plains. Mike shares his 2.5 and 10 Gbps networking upgrades, covers DIY repairs, and explores self-hosting with Oracle VPS and VPNs via Tailscale. We also break down his experience with the WHOOP fitness tracker, from sleep and recovery data to hardware upgrades. Thanks for listening! In this episode of Home Gadget Geeks, we dive into a range of captivating topics with Mike Wieger, exploring innovations in

Mike Wieger joins me to talk through the latest in home tech and personal gadgets. We cover his switch from Cox to MetroNet fiber and compare Omaha's evolving internet options, including T-Mobile and Great Plains. Mike shares his 2.5 and 10 Gbps networking upgrades, covers DIY repairs, and explores self-hosting with Oracle VPS and VPNs via Tailscale. We also break down his experience with the WHOOP fitness tracker, from sleep and recovery data to hardware upgrades. Thanks for listening! In this episode of Home Gadget Geeks, we dive into a range of captivating topics with Mike Wieger, exploring innovations in

Mike Wieger joins me to talk through the latest in home tech and personal gadgets. We cover his switch from Cox to MetroNet fiber and compare Omaha's evolving internet options, including T-Mobile and Great Plains. Mike shares his 2.5 and 10 Gbps networking upgrades, covers DIY repairs, and explores self-hosting with Oracle VPS and VPNs via Tailscale. We also break down his experience with the WHOOP fitness tracker, from sleep and recovery data to hardware upgrades. Thanks for listening! In this episode of Home Gadget Geeks, we dive into a range of captivating topics with Mike Wieger, exploring innovations in

In this episode of Medsider Radio, we sat down with Todd Usen, CEO of Adagio Medical.Adagio specializes in catheter-based ablation technologies for the treatment of cardiac arrhythmias, with a focus on ventricular tachycardia (VT).  Todd has over three decades of leadership experience in the medical technology industry, with particular expertise in commercial strategy, operational performance, and business transformation. Before joining Adagio, Todd served as CEO of Minerva Surgical, a women's health company, and as CEO of Activ Surgical, a digital surgery startup. Todd has also served in executive positions at Olympus, United States Orthopedics, Smith and Nephew, and Boston Scientific.In this interview, Todd shares insights on making usability central to commercialization strategy, leveraging breakthrough designation beyond regulatory validation, and assembling effective boards by carefully selecting both investor and independent members who bring operational expertise.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Todd Usen.

Everyone's excited during the demo. No one's using it six months later.Most HealthTech founders don't realize the real problem isn't adoption.It's overbuilding before your frontline champions are even heard.This week, I sat down with Jonathan McCoy, founder of vCare, and Rachel West, a nurse and clinical collaborator, to discuss how they co-created a robot assistant—CC—that's transforming the day-to-day lives of nurses in long-term care.When tech becomes indispensable, you know you've nailed product-market fit.What You'll Learn

Happy Wednesday, it's time for our weekly chat, wahooo.A recent piece in the New York Times asked Is All of This Self-Monitoring Making Us Paranoid? It was all about wearable health technology such as Oura rings. Oura rings are smart devices worn on the finger that contain sensors so you can track over 20 biometrics such as sleep, movement, body temperature, stress, menstrual cycles and something called daily readiness. They're between around £350 and £500, which I don't believe covers a subscription to data and insights, which is an additional monthly or yearly fee, and they promise to “empower you to prioritise your long term health goals and build healthy habits that will last a lifetime.” The New York Times piece is really interesting, and explores how this kind of data isn't always a gateway to good physical health habits, but can for some people, increase their anxiety and unhealthy body monitoring habits. We get into it and hear from you, the listeners, too!We hope you enjoy, and as always please do follow + review the show on your podcast player app as it helps others to find the podcast :)O,R,B xIs All of This Self-Monitoring Making Us Paranoid? Hosted on Acast. See acast.com/privacy for more information.

Episode 56 - Richard Harrison is a Pharmacist and the Healthcare Services Manager for Asda, where he leads the development and delivery of innovative pharmacy services across the UK. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

As healthcare systems grapple with persistent staffing shortages and rising patient volumes, the need for streamlined, tech-enabled workflows has become urgent. A 2024 time-motion study across four hospitals found that clinical pharmacists spend over 80% of their time on clinical activities, with nearly 12% dedicated to face-to-face patient interaction. That leaves less than 20% for administrative and logistical tasks like inventory management, highlighting the opportunity for automation to further maximize clinical value. Omnicell's push toward an “autonomous pharmacy” seeks to rebalance this equation by automating routine operations and freeing up clinicians for patient-facing care.Can real-world automation and AI truly relieve cognitive burden without removing the human touch from healthcare?This second episode in a two-part Highway to Health series, hosted by David Kemp, features Omnicell's Randall Lipps, CEO and founder of Omnicell, and Nish Parekh, SVP and Chief Product Officer. They discuss how robotics, RFID, and predictive analytics are transforming medication workflows while restoring human connection in clinical care.Key Takeaways:The Autonomous Pharmacy Vision: Omnicell aims to automate repetitive pharmacy tasks, allowing over 200,000 pharmacists to reengage directly in patient care.Real-World AI and RFID in Action: The lab's MedTrack OR system uses RFID to track anesthesia meds in real time, solving inventory blind spots and reducing manual counts.Collaboration is the Catalyst: Every solution stems from customer-driven feedback. The Innovation Lab is not a showroom—it's a collaborative workspace to solve “big, hairy” problems.Randall Lipps is the founder, chairman, and CEO of Omnicell, where he has led the company from a single-product startup to a global leader in pharmacy automation and medication management. Drawing from his background in airline operations and logistics, he pioneered Omnicell's vision of the Autonomous Pharmacy, now serving over 5,000 hospitals and 40,000 pharmacies worldwide. Lipps also serves on several healthcare and digital health advisory boards and is recognized for his leadership in automation, innovation, and operational efficiency.Nish Parekh is a healthcare technology executive and current SVP and Chief Product Officer at Omnicell, where she leads global product strategy, innovation, and marketing. Her career spans leadership roles at IBM Watson Health, Epic, and AppliedVR, with a focus on AI, digital therapeutics, and advancing pharmacy automation. A recognized voice in health tech, she has been featured in Fast Company, spoken at SXSW and CES, and was named one of the Top 50 Women Leaders in Health Tech.

Hospitals are facing a deepening staffing crisis that threatens care delivery. More than 540,000 healthcare workers exited the field between February 2020 and September 2021, and hospital employment declined by nearly 94,000 during the same period. Projections indicate that over 6.5 million healthcare professionals could leave the workforce by 2026, creating a net shortfall exceeding 4 million roles. This growing gap is accelerating the adoption of healthcare automation as a critical solution to reduce clinician burden, minimize errors, and maintain consistent, patient-centered care.What does meaningful innovation look like when the stakes are life and death, and how can automation empower frontline teams without sacrificing the human touch?Part one of a two-part Highway to Health series, hosted by David Kemp, takes you into Omnicell's Innovation Lab in Austin, Texas. David joins Omnicell's Nish Parekh, SVP and Chief Product Officer, and Michael Garel, Senior Director: Innovation, to explore how robotics, human-centered design, and customer collaboration are reshaping medication workflows. The conversation underscores how healthcare automation, when paired with clinical insight, can reduce cognitive burden, restore patient focus, and help providers do what they came into healthcare to do—care.Key takeaways from the episode:Automation should enhance, not replace, care: Reducing repetitive tasks allows clinicians to focus more on meaningful patient interaction.Customer input drives real innovation: Omnicell co-designs solutions alongside healthcare workers to solve urgent, real-world challenges.Speed to solution saves lives: Timely, accurate medication delivery reduces errors, shortens hospital stays, and improves patient experience.Nish Parekh is a healthcare technology executive with over 15 years of experience leading product innovation across digital health, AI, and medication management. As SVP and Chief Product Officer at Omnicell, she oversees global product strategy, marketing, and operations, and previously led IBM Watson's oncology product suite. Recognized as a Top 50 Woman Leader in Health Tech, she has been featured in Fast Company, eMarketer, and SXSW for her work in expanding access to healthcare innovation.Michael Garel is a seasoned product executive and entrepreneurial leader with deep expertise in building and scaling B2B software, hardware, and systems companies, particularly in healthcare, retail tech, and industrial computing. He has successfully led multimillion-dollar product development initiatives at companies like Omnicell, Accruent, Dell, and his own startup eyeQ—bringing disruptive technologies to market and forming strategic partnerships with major corporations such as IBM, Intel, and Samsung.

Over half of Americans now live with at least one chronic condition, yet our healthcare system still revolves around episodic, reactionary care instead of continuous, coordinated support.We talk with Dr. Jaewon Ryu—former CEO of Geisinger and now CEO of Risant Health—about how integrated delivery systems are reshaping the way care is paid for and delivered. With decades of experience spanning medicine, law, government, and leadership at some of the most respected healthcare institutions, Dr. Ryu offers a rare inside look at what it takes to scale value-based care in a fragmented system.We cover:

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. What if your blood could reveal the future of your health - years before symptoms ever appear? In this episode of Eye on AI, Craig Smith sits down with Ash Anwar, co-founder of Molecular You, to explore how AI and advanced biomarker analysis are transforming how we detect and prevent disease.  From a real-life case where stage 1 pancreatic cancer was caught early, to the science behind tracking 250+ dynamic biomarkers, Ash breaks down how Molecular You is shifting healthcare from reactive treatment to proactive longevity.  They dive into the limitations of genetic testing, the power of machine learning models trained on clinical data, and how personalized action plans are helping individuals take control of their health in real time.  If you're curious about the intersection of AI, diagnostics, and the future of preventive medicine—this is a conversation you won't want to miss. Stay Updated: Craig Smith on X: https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) How AI Can Predict Disease Before It Happens   (02:02) Meet Ash Anwar: From Scientist to Health Tech Leader   (06:31) What Is Molecular You and How It Works   (09:43) Why Biomarker Tracking Over Time Is a Game-Changer   (15:46) How Molecular You Detected Stage 1 Pancreatic Cancer   (23:15) Biomarkers vs Genetics: What Really Matters   (28:11) The AI Models Behind Early Disease Detection   (32:37) How the Product Works for Clinics and Consumers   (35:05) Who They Compete With and What Makes Them Different   (37:34) Research vs Product: The Cancer Risk Challenge   (43:43) How Often Should You Get Tested?

On today's episode, the team is joined by Hamid Tabatabaie, President & CEO of CodaMetrix, a Series B HealthTech company using AI to transform clinical coding.Hamid brings deep experience from the healthcare technology space and has been at the forefront of driving operational efficiencies in some of the most complex health systems in the U.S.The conversation kicks off with a look into Hamid's background, followed by an overview of CodaMetrix, how it began, what problem it solves, and why it matters.Key Discussion Points:

In this episode of the Boost Your Biology podcast, Lucas Aoun engages with Michael Suswal and Alina Su, co-founders of Generation Lab, to explore the intricate relationship between aging and epigenetics. They discuss how epigenetics plays a significant role in the aging process, emphasizing that 80% of aging is influenced by lifestyle and environmental factors rather than just genetics. The conversation delves into the importance of pre-disease detection, personalized health insights, and the effectiveness of various interventions such as stem cell therapy and plasma exchange. Through personal anecdotes and case studies, the hosts illustrate how data-driven approaches can optimize health and longevity, paving the way for a future where medicine is tailored to individual needs. In this conversation, Alina and Michael discuss their journey into the health tech space, focusing on the importance of measuring aging and health diagnostics. They share insights on their user demographics, the impact of their health tests, and the innovations they are developing to help individuals understand and improve their health. The conversation also touches on the philosophical implications of extended lifespan and the future of aging research

Innovation is the driving force behind unlocking better patient experiences and improving access to quality care. In this episode, Derek Streat, Co-Founder and CEO at DexCare, shares his journey of transforming healthcare access through innovative technology solutions. Derek dives into how DexCare optimizes the way health systems manage digital demand, making healthcare more accessible and efficient for both providers and patients.Specifically, Derek discusses:(03:09) The inspiration behind DexCare and its mission to streamline healthcare access.(08:52) Find one person who values your product before seeking product-market fit.(19:08) Use data to improve patient outcomes and efficiency.(25:22) Overcoming challenges in scaling a health tech startup.(31:02) Strong value attracts smart investors, even in tough markets.(36:12) Collaborate with talented people, not just your own ideas.(40:48) Closing cancer screening gaps improves health outcomes.(47:53) Digital platforms transform traditional healthcare models.(53:27) Experiment continuously; capital sustains the journey.(57:01) Key lessons from Derek's health tech journey.Resources Mentioned:Derek Streathttps://www.linkedin.com/in/derek-streat/DexCare | LinkedInhttps://www.linkedin.com/company/dexcare/DexCare | Websitehttps://dexcare.com/This episode is brought to you by:Leverage community-led growth to skyrocket your business. “From Grassroots to Greatness” by author Lloyed Lobo will help you master 13 game-changing rules from some of the most iconic brands in the world — like Apple, Atlassian, CrossFit, Harley-Davidson, HubSpot, Red Bull and many more — to attract superfans of your own that will propel you to new heights. Grab your copy today at FromGrassrootsToGreatness.com.Each year the US and Canadian governments provide more than $20 billion in R&D tax credits and innovation incentives to fund businesses. But the application process is cumbersome, prone to costly audits, and receiving the money can take as long as 16 months. Boast automates this process, enabling companies to get more money faster without the paperwork and audit risk. We don't get paid until you do! Find out if you qualify today at https://Boast.AI.Launch Academy is one of the top global tech hubs for international entrepreneurs and a designated organization for Canada's Startup Visa. Since 2012, Launch has worked with more than 6,000 entrepreneurs from over 100 countries, of which 300 have grown their startups to seed and Series A stage and raised over $2 billion in funding. To learn more about Launch's programs or the Canadian Startup Visa, visit https://LaunchAcademy.ca.Content Allies helps B2B companies build revenue-generating podcasts. We recommend them to any B2B company that is looking to launch or streamline its podcast production. Learn more at https://contentallies.com.#HealthcareInnovation #DigitalHealth #HealthTech #Product #Marketing #Innovation #StartUp #GenerativeAI #AI

In this episode of Medsider Radio, we sat down with Stuart Long, CEO of InfoBionic. InfoBionic's virtual cardiac telemetry platform, MoMe ARC®, brings together a tiered hospital-grade monitoring capability powered by advanced AI-enabled analysis for cardiac interventions.Stuart has over two decades of experience in the medical device and healthcare technology sectors, with a focus on driving rapid commercial growth. His leadership spans roles including CEO of Monarch Medical Systems, global chief marketing and sales officer at CapsuleTech, and executive positions at Philips Healthcare, Agfa HealthCare, AMICAS, and FUJIFILM USA. At CapsuleTech, he developed strategic initiatives that led to the company's acquisition by Qualcomm Life. In this interview, Stuart shares insights on combining debt and equity financing, hybrid commercial approaches, and positioning startups for acquisitions through adjacent market development — all while maintaining the persistence needed to survive the long game.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Stuart Long.

Episode 55 - Dr. Melinda Rees is CEO of Psyomics, an integrated healthtech and biotech company that brings deep clinical insight to the challenge of redesigning how we access and interact with mental health services at scale. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Is the digital health IPO drought over? Halle and Michael dig into the Hinge Health IPO and what it signals for the return of digital health companies to the public markets. They explore how much equity founders typically hold at IPO, the growing role of private equity, and why down rounds aren't the deal-breaker they once were.Plus: Elizabeth Holmes' husband launches a head-scratching startup, a former McKinsey healthcare partner faces prison time, and OpenAI teams up with the FDA.We cover:

Sheldon Inwentash, Chairman and CEO of ThreeD Capital (CSE: IDK | OTCQX: IDKFF), discusses the high-risk, high-reward world of early-stage investing.He shares how the company identifies promising innovations in tech and health, what makes a new company worth backing, and why junior companies in the resource sector still present compelling opportunities. Inwentash also gives us a look into AI/ML Innovations, a company aiming to improve heart health monitoring.Learn more about ThreeD Capital: https://www.threedcapital.com/Watch the full YouTube interview here: https://youtu.be/T8sJCLKt-fcAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

In this episode of Medsider Radio, we sat down with Shreya Mehta, co-founder and CEO of Zenflow.Zenflow is a medical device company focused on treating benign prostatic hyperplasia (BPH). A biomedical engineer, Shreya brings over 15 years of experience in medtech, including serving as a lead reviewer at the FDA, where she specialized in cardiovascular devices. Shreya co-founded Zenflow in 2014 out of the Stanford Biodesign Innovation Fellowship. The company was one of the first medical device startups backed by Y Combinator and also received early support from StartX and the UCSF Rosenman Institute at QB3.Shreya's experience at Zenflow reveals strategies for grounding innovation in patient needs, building productive FDA relationships, and leveraging accelerator programs to transform academic concepts into viable businesses.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Shreya Mehta.

Guest InformationJaya Pokuri - Co-founder, Bonfire AnalyticsVinay Nagaraj - Co-founder, Bonfire AnalyticsKey Topics DiscussedHealthcare data analytics and go-to-market strategyMachine learning applications in health tech salesProcessing prescription claims and medical dataMoving beyond volume-driven provider targetingHealthcare policy challenges and data accessCompanies and Products MentionedBonfire Analytics - Healthcare data analytics platformPoint Designs - Prosthetics device company (case study)Key Statistics3x increase in sales efficiency for Point DesignsFounded Bonfire Analytics in late 2022Target market: SMB to mid-market health tech companiesResourcesBonfire Analytics Website: https://www.bonfireanalytics.com/Using Provider Data to Sharpen Your GLP-1 GTM StrategyConnect with guests on LinkedIn: Jaya Pokuri and Vinay Nagaraj Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to sign up for our free webinars, visit www.productinhealthtech.com.

George and Louise dive into a roundup from the Australian Digital Health Festival, key government presentations and reports from the Commonwealth, Victoria and New South WalesWe cover some of the big stories coming out of Silicon Valley – there's a lot to talk about!Plus we chat with the Queen herself, Mother of FemTech, Ida Tin on “women's health as societal infrastructure”Connect with Ida on LinkedIn | Join the Book WaitlistResources:Halle Tecco on the Growth-Stage Cliff Plaguing Women's Health Startups LinkJohn Carreyrou's book Bad Blood, Secrets and Lies in a Silicon Valley StartupVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

Most HealthTech founders collect loads of patient data…But let's be honest: dashboards don't change care plans—decisions do.I sat down with Karen Josswick to uncover how HealthTech companies can stop spinning in data loops and start building real post-acute care value.We talked workflow integration, remote care planning, and how to activate the right team talents inside your org and your buyers' orgs.If you're serious about delivering outcomes that healthcare systems value, this episode is your blueprint.

Nurses are essential leaders in healthcare, extending their influence far beyond management to encompass holistic care and relationship building. In this episode, Asher Perzigian and Ajay Mody welcome Joyce Fitzpatrick, the Director of the Marian K. Shaughnessy Nurse Leadership Academy and a distinguished professor at Case Western Reserve University's Frances Payne Bolton School of Nursing, to discuss the critical role of nursing in today's healthcare landscape. Joyce encourages nurses to see themselves as leaders, to speak up, and to drive change. She highlights the significant impact of nurse leadership on decision-making processes, the global reach of nursing, and the integration of technology in patient care. Joyce teaches her students to introduce themselves confidently, network effectively, and use technology to enhance their leadership, aiming to position nurses in key decision-making roles to better represent patient needs. Join us to explore how nurses are shaping the future of healthcare and to discover their vital role as the heart and soul of the healthcare system.

US healthcare has more unproductive labor and more unstructured data than any other industry, making it both vulnerable to disruption from generative AI and especially unprepared for it.That's the provocative thesis of Eric Larsen, president of TowerBrook Advisors. In this episode, he joins host Steve Kraus to explain why generative AI is unlike any other technology we've seen—and why the $4.9 trillion healthcare sector is uniquely exposed.We cover:

Episode 54 - Dr Amar Ahmed, a GP trainer and partner with 24 years at a busy Cheshire surgery, is known for innovative, award-winning solutions that improve NHS frontline care. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

In this episode, StartUp Health co-founder Unity Stoakes sits down with Jeff Boyes, founder of Thryvly Health Tech, to explore a crucial challenge in modern healthcare: how do we go beyond breakthrough treatments to truly support patients on their long-term health journeys? Jeff dives deep into his mission to reimagine how people connect with their health, turning advanced technology into deeply personal experiences. From his early days as a teacher to building a groundbreaking platform, Jeff explains how Thryvly is setting a new standard for patient engagement and long-term wellbeing, especially within the rapidly evolving GLP-1 space. You'll learn about: Jeff's unique path into health tech, shaped by personal experience and a passion for education The core philosophy behind Thryvly: leveraging data to foster empathy, trust, and clarity for patients How Thryvly's technology supports sustained behavior change, going beyond short-term fixes The exciting future of patient-connected tech and Thryvly's role in it Why Jeff joined StartUp Health's Food As Medicine Health Moonshot Community Tune in now to hear from an innovator who is blending cutting-edge tech with an understanding of human behavior. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot Community Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Over 160 million Americans are served by Optum, yet many still don't fully understand what it actually does—or why it matters.Dr. Patrick Conway, newly appointed CEO of Optum and former head of CMS Innovation Center and Blue Cross NC, joins Steve for a wide-ranging discussion on the state of healthcare delivery, affordability, and the potential of value-based care at a national scale. With experience spanning the frontlines of medicine to top government and corporate leadership, Conway breaks down how Optum aims to improve care while controlling costs—and why he continues to practice as a pediatric hospitalist on weekends.We cover:

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

In this episode, host Eric sits down with Marco Benitez, CEO and founder of ROOK, to explore how digital health data is reshaping the fitness and healthcare landscapes. They discuss how wearable technology drives innovation in health monitoring, especially during the pandemic's impact on the industry. Marco shares his expertise in biomedical engineering and big pharma, highlighting how data-driven insights can enhance patient outcomes. The conversation dives into the challenges of standardizing wearable data, the role of AI in advancing healthcare, and the critical need for data privacy. They also examine how wearables empower disease prevention and personalized care through real-time biometric tracking. Marco wraps up by sharing Rook's mission and inviting collaborations to harness wearable data for better health and well-being.   LINKS: https://goteamup.com/ https://podcastcollective.io/ https://egym.com/int  

Nurses aren't just at the bedside—they're in boardrooms, legislatures, and labs. In this episode, Ajay Mody and Asher Perzigian sit down with Dr. Allison Norful of Columbia University and Summer Davis of the Ohio Association of Advanced Practice Nurses to unpack how nurses are reshaping healthcare. From navigating towards full practice authority to driving policy and tackling mental health, this conversation reveals the untapped power of nursing leadership in a rapidly evolving system. Part of The Heart of Healthcare series—where the future of medicine gets personal.

In this episode of Medsider Radio, we sat down with Dr. Arun Menawat, Chairman and CEO of Profound Medical. Profound is commercializing the TULSA-PRO system, an alternative approach to prostate cancer treatment that uses MRI-guided thermal ultrasound to target and eliminate cancerous tissue without surgical incisions. Before joining Profound in 2016, Arun served as the Chairman and CEO of Novadaq Technologies for 13 years, guiding the company from a startup to one of the fastest-growing, NASDAQ-listed medical technology businesses with a market cap exceeding one billion USD. Earlier in his career, Arun served as President of Cedara Software, a company that developed the industry's first medical imaging software platform. Today, it's part of IBM's Watson Health.In this interview, Arun shares insights on building credibility with physicians, the strategic approach to clinical trials that led to their recent Medicare reimbursement coverage, and his vision for transforming the future of surgery beyond prostate cancer.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Arun Menawat.

Aleisia Gibson Wright, founder of GW Health Public Relations, joins Regan Robertson for a candid conversation on how AI and storytelling are reshaping the future of healthcare. Together, they explore what it takes to build technology that doesn't leave humanity behind—and share insights from the industry's most influential marketing event, POSSIBLE 2025 in Miami.

How can you protect your practice in a mental health tech landscape that doesn't always have your best interests at heart? In this episode, I'm joined by Megan Cornish, a social worker turned writer, for a powerful conversation about the realities therapists face when working with large mental health platforms. Megan shares her own journey out of community mental health and into writing, and together we dig into how these platforms can undervalue clinicians while prioritizing profit. We talk about the venture capital model and the ways it can exploit therapists—and just as importantly, what you can do to protect yourself. Megan offers thoughtful, practical strategies to help therapists stay grounded and strategic in a shifting industry.If you've felt uneasy about the rise of mental health tech or unsure how to navigate it while staying true to your values, this episode will help you feel more informed and empowered.For a full transcript of the episode and much more, check out the blog post on our website! https://moneynutsandbolts.com/?p=17821 To watch a video version of this, check it out on YouTube: https://youtu.be/h27aRIqBiy0 Connect with Megan CornishFind Megan on LinkedIn: https://www.linkedin.com/in/megan-cornish/ Join the Facebook Group, The Fit Check for Therapists https://www.facebook.com/groups/1931610747282163/ Want to work with Linzy?Check out the FREE masterclass, The 4 Step Framework to Getting Your Business Finances Totally in Order, where you'll learn the framework that has helped hundreds of therapists go from money confusion and shame to calm and confidence, as well as the three biggest financial mistakes that therapists make. https://moneynutsandbolts.com/masterclass-signup-p/ Interested in learning more about Money Skills for Group Practice Owners? Click here to join the waitlist. https://moneynutsandbolts.com/msgpo-waitlist-2/Are you enjoying the podcast? Please help us by giving us a 5 star review. It makes a huge difference. To easily leave a review on your favorite app, follow this link: https://lovethepodcast.com/678c207559775ba176be52bf Mentioned in this episode:Check Out Relay for Business BankingStay calm and in control of your private practice finances when you sign up with Relay, my go-to online banking and money management platform. Plus, if you use my link, you'll get a $50 sign up bonus once you fund your account. *Sign Up for RelayWant to work with Linzy?Check out the FREE masterclass, The 4 Step Framework to Getting Your Business Finances Totally in Order, where you'll learn the framework that has helped hundreds of therapists go from money confusion and shame to calm and confidence, as well as the three biggest financial mistakes that therapists make. At the end, you'll be invited to join Money Skills for Therapists and get Linzy's support in getting your finances finally working for you. Click on the link to find a masterclass time that works for you!

Women make 80% of healthcare decisions and outspend men two to one on care—yet when it comes to designing, funding, and scaling health tech, they're still treated like a niche.In this episode, we break down the broken flywheel holding women's health innovation back including fewer growth-stage investments, limited exits, and a system not built to serve women as the primary users of care. I'm joined by Carolyn Witte, co-founder of Tia, and Katie Drasser, CEO of Rock Health, to talk about what needs to change—and how we get there.We cover:

Innovative partnerships and culturally tailored approaches are essential to expanding access to behavioral health services and addressing critical gaps in care. In this episode, Luis Suarez, CEO of Sanarai, and Stella Tran, Senior Program Investment Officer of the California Health Care Foundation, talk about the importance of building trust and leveraging cultural competence. Luis shares how his organization provides culturally relevant mental health services for Spanish-speaking communities, addressing a critical gap in access. Stella discusses how her foundation uses innovation as a lever to improve care quality and access for low-income populations. Tune in to discover how innovation and cultural competence are transforming behavioral health access for underserved communities! Resources: Connect with and follow Luis Suarez on LinkedIn. Connect with and follow Stella Tran on LinkedIn. Follow Sanarai on LinkedIn and explore their website. Follow the California Health Care Foundation on LinkedIn and discover their website. Listen to the podcast Making Waves in Health Tech here.

In this month's Digital Health Download, Steve and Halle unpack the headlines shaping healthcare, policy, and technology—with an eye toward where things may be heading next. From shifting political support for Medicaid and the ACA to state-level action on PBMs, they explore the unexpected ways the system is evolving.We cover:

Young physicians are primarily motivated by a desire to help and heal, not by prestige or financial gain.  In this episode, Kristin Apple, President of the Linus Group, and Chris Moniz, Managing Director of Healthtech at HSBC Innovation Banking, discuss the findings of the "Health 2035" report, highlighting insights from a survey of 1,000 young physicians and over 40 health care visionaries. Kristin delves into their aspirations for preventative care, their increasing concern about patient trust, and their eagerness to integrate AI into their practices, although not at the expense of the human connection. Chris adds his perspective on the investment trends backing these preferences, focusing on increased funding for provider operations.  Join us and learn how the healthcare landscape is poised to shift towards a more preventative, tech-enabled, and community-centered approach! Resources: Connect with and follow Chris Moniz on LinkedIn. Discover more about HSBC on LinkedIn and visit their website. Follow and connect with Kristin Apple on LinkedIn. Learn more about LINUS on their LinkedIn and website. Check out the Health 2035 Report here.